Co-Processed Excipients Research:CAGR of 4.6% during the forecast period

QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report "Co-Processed Excipients- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Co-Processed Excipients market, including market size, share, demand, industry development status, and forecasts for the next few years.

The global market for Co-Processed Excipients was estimated to be worth US$ 2362 million in 2025 and is projected to reach US$ 3224 million, growing at a CAGR of 4.6% from 2026 to 2032.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5509441/co-processed-excipients

Co-Processed Excipients Market Summary

A co-processed excipient is a combination of two or more compendial or non-compendial excipients designed to physically modify their properties in a manner not achievable by simple physical mixing, and without significant chemical change. However, in some instances, formation of necessary components may occur, such as in-situ salt formation.

According to the new market research report "Global Co-Processed Excipients Market Report 2025-2031", published by QYResearch, the global Co-Processed Excipients market size is projected to reach USD 3.1 billion by 2031, at a CAGR of 4.6% during the forecast period.

Figure00002. Global Co-Processed Excipients Market Size (US$ Million), 2020-2031

Co-Processed Excipients

Above data is based on report from QYResearch: Global Co-Processed Excipients Market Report 2024-2031 (published in 2024). If you need the latest data, plaese contact QYResearch.

Figure00003. Global Co-Processed Excipients Top 11 Players Ranking and Market Share (Ranking is based on the revenue of 2024, continually updated)

Co-Processed Excipients

Above data is based on report from QYResearch: Global Co-Processed Excipients Market Report 2024-2031 (published in 2024). If you need the latest data, plaese contact QYResearch.

According to QYResearch Top Players Research Center, the global key manufacturers of Co-Processed Excipients include Roquette, JRS Pharma, IFF (DuPont), Colorcon, Meggle, Daicel Corporation, BASF, Fuji, ABF Ingredients, Shin-Etsu, etc. In 2024, the global top five players had a share approximately 25.0% in terms of revenue.

Figure00004. Co-Processed Excipients, Global Market Size, Split by Product Segment

Co-Processed Excipients

Based on or includes research from QYResearch: Global Co-Processed Excipients Market Report 2024-2031.

In terms of product type, currently Granulation is the largest segment, hold a share of 40.0%.

In terms of product application, currently Pharmaceuticals is the largest segment, hold a share of 67.9%.

Market Drivers:

D1: The relentless growth of the global pharmaceutical industry-fueled by expanding healthcare access, rising prevalence of chronic diseases, and ongoing innovation in therapeutic modalities-creates steady and increasing demand for reliable, high-performance excipients.

D2: As excipient manufacturers consolidate through M&A, larger suppliers with broader portfolios can invest in co-processed lines and market them as turnkey solutions. This changes buyer behavior: large pharma and CDMOs may prefer to standardize on a single qualified supplier to streamline audits, quality agreements, and logistics. The market therefore responds to the structure of the supplier base - where a few global players push co-processed offerings, adoption accelerates; in fragmented markets, adoption is slower because qualification pluralities remain manageable for buyers.

D3: Sustainability and circularity/regulatory environmental pressures are an emergent driver with a different emphasis from earlier sustainability points. Beyond renewable raw materials, corporate ESG programs and procurement policies increasingly require suppliers to disclose scope 1-3 emissions, water use, and waste management. Co-processed excipient producers that can demonstrate lower lifecycle environmental impact per tablet (fewer processing steps at the drugmaker, less material handling) gain preference. In some cases, regulatory incentives or corporate carbon targets create economic drivers that tilt purchasing toward co-processed, lower-footprint options.

Restraint:

R1: A major restraint from the user side is dependence on single suppliers. Many co-processed excipients are proprietary formulations protected by intellectual property or patented manufacturing methods. Once a pharmaceutical company incorporates such an excipient into an approved formulation, switching suppliers post-approval becomes highly complex and expensive due to regulatory revalidation requirements. This creates a perception of supply risk, particularly if the original supplier discontinues the product or experiences production issues. As a result, formulators may avoid co-processed materials despite their performance advantages, preferring traditional excipients with multiple supply sources.

R2: While co-processed excipients are often marketed as multifunctional and versatile, they are still standardized blends designed for general-purpose use. For highly specialized formulations-such as controlled-release, moisture-sensitive, or high-potency drugs-the available commercial co-processed excipients may not meet exact performance requirements. Because modifying a co-processed excipient typically requires proprietary process changes, formulators cannot easily tailor the material to their specific API needs. This limited customization flexibility can discourage adoption among advanced formulation developers seeking precise control over tablet behavior.

R3: Global supply chain volatility has exposed vulnerabilities in excipient sourcing. Co-processed excipients, often produced in limited quantities or specialized facilities, are more susceptible to disruptions caused by geopolitical tensions, transportation delays, or raw material shortages. The reliance on complex production equipment and region-specific manufacturing sites means that scaling up or relocating production can be challenging. Any interruption in supply can directly impact pharmaceutical production schedules, leading formulators to favor conventional excipients that are more readily available from multiple vendors.

Trend:

Shift Toward Functionality and Performance-Based Excipients: One of the most significant trends shaping the co-processed excipients industry is the move from traditional excipients to functionality-based excipient systems. Historically, excipients were viewed as inert substances that merely served as fillers, binders, or disintegrants. However, modern drug development increasingly recognizes excipients as key formulation enablers. Co-processed excipients exemplify this evolution by delivering multifunctional performance-enhancing flow properties, tablet hardness, disintegration, and content uniformity simultaneously. As new active pharmaceutical ingredients (APIs) become more potent, sensitive, and poorly compressible, formulators are turning to co-processed excipients to overcome these challenges without resorting to complex granulation processes. This functional transformation aligns with the pharmaceutical industry's broader shift toward efficiency, robustness, and reduced processing steps.

Expansion of Direct Compression Formulations: The expansion of direct compression (DC) technology is another major driver of co-processed excipient development. Direct compression simplifies tablet manufacturing by eliminating wet granulation and drying steps, significantly reducing time, cost, and energy consumption. However, DC requires excipients with exceptional flowability and compressibility-properties not always achievable through traditional materials. Co-processed excipients like MCC-lactose or MCC-mannitol blends are specifically engineered for this purpose, providing uniform particle size, reduced segregation, and consistent die filling. The increasing industrial adoption of DC, particularly in generic drug production, is accelerating the demand for co-processed excipients that can perform well under high-speed tableting conditions and maintain tablet uniformity even with low-dose or moisture-sensitive APIs.

Growing Use in Orally Disintegrating and Patient-Centric Formulations: Another major trend is the increasing use of co-processed excipients in orally disintegrating tablets (ODTs) and other patient-centric dosage forms. Modern consumers, especially pediatric and geriatric populations, prefer formulations that are easy to swallow and pleasant in taste. Co-processed excipients containing mannitol, sorbitol, or other sugar alcohols are commonly employed to provide rapid disintegration, good mouthfeel, and taste-masking capabilities. Their ability to balance mechanical strength and fast disintegration makes them ideal for ODT manufacturing, which demands both robustness during packaging and rapid dissolution upon administration. The trend toward self-administration, improved patient compliance, and personalized dosing formats further supports the integration of co-processed excipients into new drug delivery systems, including chewable tablets, sublinguals, and dispersible powders.

Regulatory Recognition and Standardization Efforts: Regulatory acceptance is another important trend in the co-processed excipient industry. While co-processed excipients are composed of existing, pharmacopeia-listed materials, their combination creates a new physical entity that requires characterization and justification for regulatory submission. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have gradually acknowledged co-processed excipients as legitimate formulation components, provided their safety, performance, and stability are well-documented. The increasing publication of monographs and quality standards for co-processed excipients in compendia such as the European Pharmacopoeia (Ph. Eur.) and United States Pharmacopeia (USP) is a clear sign of regulatory progress. This recognition helps reduce barriers to market entry and encourages further innovation in excipient development.

The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively.

The Co-Processed Excipients market is segmented as below:
By Company
Meggle
Roquette
BASF
JRS Pharma
ABF Ingredients
Colorcon
Daicel Corporation
Shin-Etsu
IFF (DuPont)
Fuji
Topchain

Segment by Type
Granulation
Spray Drying
Hot Melt Extrusion
Solvent Evaporation
Others

Segment by Application
Pharmaceuticals
Nutraceuticals

Each chapter of the report provides detailed information for readers to further understand the Co-Processed Excipients market:

Chapter 1: Introduces the report scope of the Co-Processed Excipients report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2021-2032)
Chapter 2: Detailed analysis of Co-Processed Excipients manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2021-2026)
Chapter 3: Provides the analysis of various Co-Processed Excipients market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2021-2032)
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2021-2032)
Chapter 5: Sales, revenue of Co-Processed Excipients in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2021-2032)
Chapter 6: Sales, revenue of Co-Processed Excipients in country level. It provides sigmate data by Type, and by Application for each country/region.(2021-2032)
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2021-2026)
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Benefits of purchasing QYResearch report:

Competitive Analysis: QYResearch provides in-depth Co-Processed Excipients competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge.

Industry Analysis: QYResearch provides Co-Processed Excipients comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis.

and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions.

Market Size: QYResearch provides Co-Processed Excipients market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development.

Other relevant reports of QYResearch:
Global Co-Processed Excipients Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
Global Co-Processed Excipients Market Research Report 2026

About Us:
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 19 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
Email: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

This release was published on openPR.